Amicus Therapeutics ((FOLD)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Amicus Therapeutics recently completed a study titled An Open-Label, Multi-Center, International Study to Investigate Drug-Drug Interactions Between AT2220 and Alglucosidase Alfa in Patients With Pompe Disease. The study aimed to evaluate the interactions between duvoglustat (AT2220) and alglucosidase alfa (rhGAA) in Pompe Disease patients, focusing on safety and pharmacokinetics. This research holds significance as it explores potential improvements in treatment efficacy for a rare genetic disorder.
Intervention/Treatment: The study tested the effects of duvoglustat, an oral drug, in combination with rhGAA, an intravenous infusion. The purpose was to assess how duvoglustat affects the pharmacokinetics and safety of rhGAA in treating Pompe Disease.
Study Design: This was an open-label, non-randomized, parallel assignment study with no masking. The primary purpose was treatment-focused, aiming to understand the drug-drug interaction between duvoglustat and rhGAA.
Study Timeline: The study began on October 31, 2011, with primary completion in 2018. The last update was submitted on June 24, 2025. These dates highlight the study’s long-term commitment to understanding treatment interactions in Pompe Disease.
Market Implications: The completion of this study could positively influence Amicus Therapeutics’ stock performance by demonstrating their commitment to advancing treatments for rare diseases. This update may boost investor confidence, especially as the company competes in a niche market with few direct competitors.
The study is completed, with further details available on the ClinicalTrials portal.